Skip to Main Content

Paper Details

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
Eur J Cancer
49
2021
PATIENTS, Patients, advanced melanoma, hyperthyroidism, hypothyroidism, melanoma, patients, pembrolizumab, pneumonitis
Author NameAffiliation
Caroline RobertInstitut de Cancerologie Gustave Roussy, France Paris-Saclay University, CNRS UMR 3348
Antoni RibasDepartment of Medicine and the Jonsson Comprehensive Cancer Center, University of California, Los Angeles (university of california los angeles)
Antoni RibasDepartment of Medicine and the Jonsson Comprehensive Cancer Center, University of California, Los Angeles (university of california los angeles)
Peter HerseyThe University of Sydney, Australia Centenary Institute, Australia Melanoma Institute Australia
Richard W JosephMayo Clinic Cancer Center-Florida
Georgina V LongMelanoma Institute Australia, The University of Sydney, Australia Royal North Shore Hospital, Australia Mater Hospital
Reinhard DummerUniversity Hospital Zurich, University of Zurich
Reinhard DummerUniversity Hospital Zurich, University of Zurich
Anthony M JoshuaMelanoma Institute Australia, The University of Sydney, Princess Margaret Cancer Centre, University Health Network, 610 University Ave, Canada The Kinghorn Cancer Centre at St Vincent's Hospital, Australia St Vincent's Clinical School
  • 1 - 9

Datasets